Key result
Clopidogrel acts as a potent antithrombotic drug by inhibiting the binding of ADP to its low-affinity platelet receptors via a short-lasting liver metabolite.
Population
Rats and human volunteers (as discussed in the context of mechanism of action review)
Design
Review
Authors
Loading...
Clopidogrel advances ADP-targeted antiplatelet options; leaves open its clinical positioning pending outcome trials.
Clopidogrel acts as a potent antithrombotic drug by generating a liver metabolite that selectively inhibits ADP binding to low-affinity platelet receptors.
Savi et al. (1998) reported a review. Clopidogrel was evaluated. Clopidogrel acts as a potent antithrombotic drug by inhibiting the binding of ADP to its low-affinity platelet receptors via a short-lasting liver metabolite.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: